Table 1.
Baseline Characteristics of HIV-LIVE Study Participants—HIV-Infected Persons with a History of Alcohol Problems
| Total (n=308) | FIB-4 <1.45 (n=187) | FIB-4 1.45–3.25 (n=90) | FIB-4 >3.25 (n=31) | p-value | |
|---|---|---|---|---|---|
| Male [n (%)] | 225 (73.1) | 136 (72.7) | 68 (75.6) | 21 (67.7) | 0.69 |
| Age (mean±SD) | 42±7.3 | 40±6.9 | 46±6.6 | 46±6.6 | <0.01 |
| HCV infection (HCV RNA) (n=307) [n (%)] | 150 (48.9) | 67 (35.8) | 57 (64.0) | 26 (83.9) | <0.01 |
| CD4 count [cells/mm3] (n=289) | <0.01 | ||||
| <200 [n (%)] | 54 (18.7) | 27 (15.3) | 18 (21.4) | 9 (31.0) | |
| 200–500 [n (%)] | 121 (41.9) | 63 (35.8) | 40 (47.6) | 18 (62.1) | |
| >500 [n (%)] | 114 (39.4) | 86 (48.9) | 26 (31.0) | 2 (6.9) | |
| HIV RNA viral load [copies/ml] (n=274) | 0.72 | ||||
| <500 [n (%)] | 121 (44.2) | 76 (46.1) | 34 (42.0) | 11 (39.3) | |
| ≥500 [n (%)] | 153 (55.8) | 89 (53.9) | 47 (58.0) | 17 (60.7) | |
| Current antiretroviral therapy | 186 (60.4) | 113 (60.4) | 52 (57.8) | 21 (61.7) | 0.62 |
| Body mass index [kg/m2] (n=293) (mean±SD) | 27±5.5 | 27±6.0 | 26±5.0 | 26±3.2 | 0.08 |
| Diabetes mellitusa | 18 (5.8) | 5 (2.7) | 9 (10) | 4 (12.8) | 0.01 |
| Injection drug use, ever [n (%)] (n=307) | 165 (53.7) | 74 (39.6) | 65 (73.0) | 26 (83.9) | <0.01 |
| Current marijuana use | 119 (38.6) | 75 (40.1) | 32 (35.6) | 12 (38.7) | 0.77 |
| Heavy alcohol use (NIAAA definition) [n (%)] (n=307) | 101 (32.9) | 61 (32.8) | 30 (33.3) | 10 (32.3) | 0.99 |
| IL-6 (n=237) | |||||
| Median (IQR) | 2.80 (1.52–4.78) | 2.34 (1.26–3.67) | 3.21 (1.77–5.36) | 6.17 (3.26–10.05) | <0.01 |
| Range | 0.15–45.17 | 0.15–18.56 | 0.15–45.17 | 1.28–14.06 | |
| Tertiles [n (%)] | |||||
| 1st tertile (<1.96) | 79 (33.3) | 57 (38.8) | 20 (27.8) | 2 (11.1) | <0.01 |
| 2nd tertile (1.96–3.70) | 90 (33.8) | 55 (37.4) | 22 (30.6) | 3 (16.7) | |
| 3rd tertile (≥3.71) | 89 (32.9) | 35 (23.8) | 30 (41.7) | 13 (72.2) | |
| IL-10 (n=263) | |||||
| Median (IQR) | 5.15 (3.08–8.39) | 4.52 (2.76–7.43) | 6.3 (4.25–9.16) | 5.68 (3.3–14.94) | 0.02 |
| Range | 0.12–61.08 | 0.12–59.95 | 0.12–28.89 | 1.12–61.08 | |
| Tertiles [n (%)] | |||||
| 1st tertile (<3.64) | 83 (31.6) | 60 (37.0) | 16 (20.8) | 7 (29.2) | 0.08 |
| 2nd tertile (3.64–6.90) | 93 (35.4) | 57 (35.2) | 28 (36.4) | 8 (33.3) | |
| 3rd tertile (≥6.91) | 87 (33.1) | 45 (27.8) | 33 (42.9) | 9 (37.5) | |
| TNF-α (n=263) | |||||
| Median (IQR) | 7.25 (4.87–10.01) | 6.44 (4.82–9.22) | 7.68 (5.41–10.67) | 8.31 (5.67–13.19) | 0.06 |
| Range | 0.63–149.68 | 1.66–49.04 | 0.63–149.68 | 1.30–30.27 | |
| Tertiles [n (%)] | |||||
| 1st tertile (<5.41) | 85 (32.3) | 60 (37.0) | 19 (24.7) | 6 (25.0) | 0.06 |
| 2nd tertile (5.41–9.06) | 91 (34.6) | 59 (36.4) | 25 (32.5) | 7 (29.2) | |
| 3rd tertile (≥9.07) | 87 (33.1) | 45 (26.5) | 33 (42.9) | 11 (45.8) | |
a
Self-reported.
SD, standard deviation; IQR, interquartile range; HCV, hepatitis C virus; IL-6, interleukin 6; TNF-α, tumor necrosis factor alpha.